It’s resolution season. January is when we take stock of what went well last year and what we’d like to change going forward. We’ll get more exercise, join a gym, break out the running shoes. We’ll change our diet to offset the indulgences of December’s party season. So many good intentions -- and then February comes with its shiny heart shaped chocolate boxes. A rainy March keeps the running shoes perched by the back door. And the gym? It’s slipped down the to-do list below groceries and taking the dog to the vet. Keeping resolutions is hard. But there’s a good reason to commit to those lifestyle changes that keep you healthy: it may lower your risk of cancer. Now’s the time.
Seattle Cancer Care Alliance (SCCA) has been a leader in developing and advancing immunotherapy for cancer since our founding. Today, we are one of the first cancer centers in the U.S., and the only in the Northwest, to offer axi-cel (brand name Yescarta™), a promising new immunotherapy for patients with certain types of non-Hodgkin lymphoma.
This week, dozens of Seattle Cancer Care Alliance (SCCA) doctors and researchers are traveling to Atlanta to participate in the American Society of Hematology (ASH) 59th annual meeting. ASH brings together more than 25,000 clinicians and scientists from around the world to learn about the latest scientific updates in hematology related to malignant and non-malignant cancer types. As a leader in immunotherapy, hematology and bone marrow transplantation, SCCA is honored and excited to contribute to advancing new treatments for these diseases.
SCCA among first cancer treatment centers in country - and only in NW - to offer axi-cel (YESCARTA™) -- ground-breaking new immunotherapy
Seattle Cancer Care Alliance (SCCA) has been a leader in immunotherapy since it was first introduced as a form of treatment for certain cancers decades ago. Today, we’ve been selected as the only certified treatment center in the Northwest to offer axicabtagene ciloleucel (axi-cel, also known by the brand name YESCARTA™), a new immunotherapy that uses engineered cell therapy to harnesses the power of a patient’s own immune system to treat adults with aggressive non-Hodgkin lymphoma (NHL).